Pioneering evidence-based treatments for substance addictions
Increasing evidence-based treatment is a key component of the Addictions Program at Children’s National Hospital, created in 2022 and led by Sivabalaji Kaliamurthy, MD. In addition to evidence-based treatment and prevention efforts, the team also prioritizes engagement and education. The team collaborates with area pediatricians, who are often the first providers to identify substance use. Pediatric residents rotate with the program during their adolescent medicine blocks and child and adolescent psychiatry fellows have dedicated time with the Addictions Program to increase their knowledge and comfort in managing substance use and often co-occurring psychiatric disorders. “We really want to focus on intervening in an evidence-based manner in the primary care setting because that is where most of our patients are going to first access care outside of the emergency room,” says Dr. Kaliamurthy.
The challenge
The most common substances kids use or experiment with are alcohol, nicotine and cannabis. The team at Children’s National is focusing on the significant increase in potency of substances over the last decade. For example, cannabis potency is based on the amount of tetrahydrocannabinol (THC), and over the last 10 years, average potency in the plant product has gone from 2-5% THC to 20-25% THC. There are also higher potency products that can be vaped which contain upwards of 80% THC, which kids prefer due to ease in concealability. “It’s not the same drugs anymore that the parents’ generation might have used or experimented with when they were high schoolers, even though it’s still nicotine and cannabis, the potency has significantly changed,” says Dr. Kaliamurthy.
In addition to prevention tactics, the team at Children’s National is prioritizing the development of evidence-based treatment for patients in the Addictions Program. “Children need more tailored intervention that simply doesn’t have the same robust evidence basis that we have for adults. Right now, we are prioritizing implementing treatments that have been successful in limited research settings and studying how it translates into real world clinical settings for kids,” explains Dr. Kaliamurthy.
The challenge of treating cannabis use disorder and cannabis use disorder with co-occurring mental health conditions is that there are no effective FDA-approved medications for cannabis use disorder. Alcohol, opioids and nicotine all have many FDA-approved medication options for adults that can be used as part of a child’s treatment, off label. Dr. Kaliamurthy notes, “that is one of the directions that we will also be taking in the future — how we can effectively treat cannabis use and cannabis use co-occurring with very severe mental health conditions.”
What’s next?
Addressing community misinformation and the stigma surrounding substance use treatment has led to the development of several priority projects, including:
- Increasing education and access to information for staff at Children’s National. Ensuring that if any clinician at Children’s National meets a child that is struggling, they know where to go for regional resources and what to do for next steps to get support and help for the patient. Dr. Kaliamurthy led a project to develop resources on an intranet site available to all staff.
- Increasing access to care. Kaliamurthy is piloting a team of peer recovery support specialists. “We know that peers are people with lived experience who are in recovery, and they’ve been very effective in the adult world in really helping patients engage and connect with care.” This is a novel program launching with our youth in the emergency room.
- Focusing on cannabis. With the increase in the number of kids coming to the hospital for cannabis-related reasons and the lack of effective treatments, we are going to be focusing on effectively treating cannabis use and cannabis use with co-occurring mental health conditions.